Literature DB >> 16757523

Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance.

Annette M Chang1, Marla J Smith, Andrzej T Galecki, Cathie J Bloem, Jeffrey B Halter.   

Abstract

CONTEXT: Glucose tolerance declines with age and may involve impaired beta-cell sensitivity to glucose and beta-cell compensation for insulin resistance.
OBJECTIVE: We investigated beta-cell sensitivity to glucose and beta-cell compensation for nicotinic acid-induced insulin resistance in young (age <35 yr) people with normal glucose tolerance (NGT) and old (age >60 yr) people with NGT and impaired glucose tolerance (IGT). DESIGN/PATIENTS/SETTING/INTERVENTION: Fifteen young NGT, 16 old NGT, and 14 old IGT were randomized to 2-wk treatment with nicotinic acid or placebo in a double-blind, crossover study in a university medical setting. At the end of each treatment period, participants had a frequently sampled iv glucose tolerance test and ramp clamp, in which insulin secretion rates (ISR) were determined in response to a matched 5-10 mm glucose stimulus. MAIN OUTCOME MEASURES: Insulin sensitivity (S(I)), acute insulin response to iv glucose (AIRg), and disposition index (AIRg x S(I), or beta-cell compensation for insulin resistance) from frequently sampled iv glucose tolerance testing, and ISR area under the curve (or beta-cell sensitivity to glucose) from ramp clamp were determined.
RESULTS: Progressive impairments in insulin secretion as assessed by AIRg, disposition index, and ISR area under the curve were identified in older people with NGT, with more marked defects in older people with IGT. Nicotinic acid treatment significantly reduced S(I) in all groups. beta-Cell compensation for nicotinic acid-induced insulin resistance was incomplete in all three groups, with greater defects in the two older groups.
CONCLUSIONS: Human aging is associated with impaired beta-cell sensitivity to glucose and impaired beta-cell compensation to insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757523     DOI: 10.1210/jc.2006-0913

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  Stem cells, their niches and the systemic environment: an aging network.

Authors:  Daniela Drummond-Barbosa
Journal:  Genetics       Date:  2008-12       Impact factor: 4.562

Review 2.  Cardiometabolic impact of non-statin lipid lowering therapies.

Authors:  Parag Goyal; Leon I Igel; Keith LaScalea; William B Borden
Journal:  Curr Atheroscler Rep       Date:  2014-02       Impact factor: 5.113

3.  Excess vitamin intake: An unrecognized risk factor for obesity.

Authors:  Shi-Sheng Zhou; Yiming Zhou
Journal:  World J Diabetes       Date:  2014-02-15

4.  Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].

Authors:  Aimo Kannt; Anja Pfenninger; Anke Tönjes; Matthias Blüher
Journal:  Diabetologia       Date:  2015-06-26       Impact factor: 10.122

5.  Excess body mass index-years, a measure of degree and duration of excess weight, and risk for incident diabetes.

Authors:  Joyce M Lee; Achamyeleh Gebremariam; Sandeep Vijan; James G Gurney
Journal:  Arch Pediatr Adolesc Med       Date:  2012-01

Review 6.  Type 2 diabetes mellitus in older adults: clinical considerations and management.

Authors:  Srikanth Bellary; Ioannis Kyrou; James E Brown; Clifford J Bailey
Journal:  Nat Rev Endocrinol       Date:  2021-06-25       Impact factor: 43.330

7.  Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.

Authors:  John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

8.  Nicotinamide overload may play a role in the development of type 2 diabetes.

Authors:  Shi-Sheng Zhou; Da Li; Wu-Ping Sun; Ming Guo; Yong-Zhi Lun; Yi-Ming Zhou; Fu-Cheng Xiao; Li-Xin Jing; Shen-Xia Sun; Li-Bin Zhang; Ning Luo; Fu-Ning Bian; Wei Zou; Lai-Bin Dong; Zhi-Gang Zhao; Sheng-Fan Li; Xiao-Jie Gong; Zeng-Guo Yu; Chang-Bin Sun; Cong-Long Zheng; Dong-Ju Jiang; Zheng-Ning Li
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 9.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

10.  Short-term exercise improves beta-cell function and insulin resistance in older people with impaired glucose tolerance.

Authors:  Cathie J Bloem; Annette M Chang
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.